The pan-Canadian Oncology Drug Review (pCODR) was established by the provincial and territorial Ministries of Health to assess the clinical evidence and cost effectiveness of new cancer drugs and to use this information to make recommendations to the provinces and territories to guide their drug funding decisions. It evolved from the interim Joint Oncology Drug Review (JODR), which demonstrated the significant value that a national collaborative platform provides to cancer care decision making. The pCODR process brings consistency and clarity to the cancer drug review process, ensuring individual provinces and territories can make drug funding decisions informed by evidence. Along with the provincial and territorial Ministries of Health, with the exception of Quebec, other partners in the pCODR process are provincial cancer agencies, the Canadian Partnership Against Cancer and the Canadian Agency for Drugs and Technology in Health.